Omeros Corporation announced on March 13, 2025, that it received a funding commitment of $4.02 million from the National Institute on Drug Abuse (NIDA). This commitment is for the upcoming year, from April 1, 2025, through March 31, 2026.
The grant will fund the Phase 1b clinical development of OMS527, Omeros’ lead orally administered phosphodiesterase 7 (PDE7) inhibitor. OMS527 is being developed to treat cocaine use disorder (CUD), with the goal of reducing or eliminating craving and relapse in patients.
Securing this non-dilutive funding is significant as it supports the advancement of a key pipeline program without requiring additional equity financing. This helps to conserve the company's capital and addresses a critical area of unmet medical need in addiction treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.